生命科学资讯

Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges

Pfizer dips on new data for obesity drug acquired in $10B deal

Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b

Pfizer takes $4.4B charge related to cancer drug in fourth-quarter earnings

Pfizer’s Metsera-originated monthly GLP-1 cuts weight by 10.5% at six months

Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ

Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs

Pfizer to depart GSK's ViiV as Shionogi doubles its stake

JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year

At FDA's request, Pfizer helps ease shortage of potential autism drug

Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential

French biotech Enodia gets €20.7M aided by Pfizer for protein degrader work

Updated: Pfizer discloses patient death in Hympavzi hemophilia trial

Novo files for CagriSema approval; Merck and Pfizer’s trial win

Chutes & Ladders—Pfizer RNA leader runs to Replicate

Pfizer bets big on obesity to offset major patent cliff

FDA ‘proactively’ hands J&J a voucher; Pfizer issues 2026 forecasts

Pfizer, Sanofi pull out checkbooks for separate year-end autoimmune pacts

Pfizer adds heft to obesity pipeline in $2B Yaopharma deal

Pfizer continues renewed obesity push with $150M upfront for Fosun unit's GLP-1 drug